EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 247 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... May 10, 2022 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... September 30, 2021 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... December 12, 2025 Load more HOT NEWS Color-Blind Groom Sees Color For First Time After Bride Surprises Him... Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which... FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle...
